Influence of CYP2C19 genotype on antiplatelet treatment outcomes after percutaneous coronary intervention in patients with coronary heart disease

Yu,Dongbiao; Ma,Likun; Zhou,Junling; Li,Longwei; Yan,Wu; Yu,Xiaofan

doi:10.3892/etm.2020.8592

Influence of CYP2C19 genotype on antiplatelet treatment outcomes after percutaneous coronary intervention in patients with coronary heart disease

Authors:
- Dongbiao Yu
- Likun Ma
- Junling Zhou
- Longwei Li
- Wu Yan
- Xiaofan Yu
View Affiliations

Affiliations: Department of Cardiology, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, P.R. China
Published online on: March 11, 2020 https://doi.org/10.3892/etm.2020.8592
Pages: 3411-3418

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the study was to compare the clinical efficacy and safety of ticagrelor and clopidogrel in patients with coronary heart disease one year after percutaneous coronary intervention (PCI), and to explore their association with the CYP2C19 gene polymorphism. A total of 971 patients with coronary heart disease who were hospitalized and underwent PCI from April 2016 to May 2017 were studied. All 971 patients were divided into three subgroups according to CYP2C19 gene types as fast metabolizing, slow metabolizing and very slow metabolizing type. Patients were also classified according to the oral antiplatelet aggregation drugs they received: clopidogrel group and ticagrelor group. The incidence of major adverse cardiac events (MACE) and bleeding events in the clopidogrel‑treated and ticagrelor‑treated groups and in patients with fast, slow, and very slow CYP2C19 metabolisms were compared. Binary logistic regression analysis was carried out to analyze the risk factors associated with MACEs and hemorrhagic events. Patients on ticagrelor had a greater number of bleeding complications compared to those on clopidogrel (P<0.001), with no difference in MACE between the two groups (P=0.399). The incidence of MACE was significantly higher in very slow metabolizing patients receiving clopidogrel (P<0.001) while the incidence of bleeding complications was significantly higher in fast metabolizing patients receiving ticagrelor (P<0.001). The regression analysis revealed that the CYP2C19 gene mutation, a dual‑antiplatelet therapy, and a stroke history were all significantly associated with MACE. By contrast, a dual‑antiplatelet therapy and a stroke history were significantly associated with bleeding events. Findings of the present study indicated that clopidogrel and ticagrelor were equally efficacious post‑PCI. Efficacy of clopidogrel was reduced in patients with very slow CYP2C19 genotype while bleeding complications were higher in patients with fast CYP2C19 genotype receiving ticagrelor. CYP2C19 genotyping may be used to provide guidance to optimize individual antiplatelet treatment.

View Figures

View References

1	Mejin M, Tiong WN, Lai LYH, Tiong LL, Bujang AM, Hwang SS, Ong TK and Fong AY: CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention. Int J Clin Pharm. 35:621–628. 2013.PubMed/NCBI View Article : Google Scholar
2	Oestreich JH, Best LG and Dobesh PP: Prevalence of CYP2C19 variant alleles and pharmacodynamic variability of aspirin and clopidogrel in Native Americans. Am Heart J. 167:413–418. 2014.PubMed/NCBI View Article : Google Scholar
3	Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tantry US, Gibson Q, et al: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 302:849–857. 2009.PubMed/NCBI View Article : Google Scholar
4	Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al: 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 124:e574–e651. 2011.PubMed/NCBI View Article : Google Scholar
5	Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, et al: ESC Committee for Practice Guidelines: ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 32:2999–3054. 2011.PubMed/NCBI View Article : Google Scholar
6	Fricke-Galindo I, Céspedes-Garro C, Rodrigues-Soares F, Naranjo ME, Delgado Á, de Andrés F, López-López M, Peñas-Lledó E and LLerena A: Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations. Pharmacogenomics J. 16:113–123. 2016.PubMed/NCBI View Article : Google Scholar
7	Sorich MJ, Rowland A, McKinnon RA and Wiese MD: CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: A meta-analysis. Circ Cardiovasc Genet. 7:895–902. 2014.PubMed/NCBI View Article : Google Scholar
8	Vercellino M, Sànchez FA, Boasi V, Perri D, Tacchi C, Secco GG, Cattunar S, Pistis G and Mascelli G: Ticagrelor versus clopidogrel in real-world patients with ST elevation myocardial infarction: 1-year results by propensity score analysis. BMC Cardiovasc Disord. 17(97)2017.PubMed/NCBI View Article : Google Scholar
9	Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al: PLATO Investigators: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 361:1045–1057. 2009.PubMed/NCBI View Article : Google Scholar
10	Dayoub EJ, Seigerman M, Tuteja S, Kobayashi T, Kolansky DM, Giri J and Groeneveld PW: Trends in Platelet Adenosine Diphosphate P2Y12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016. JAMA Intern Med. 178:943–950. 2018.PubMed/NCBI View Article : Google Scholar
11	Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, et al: Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 360:354–362. 2009.PubMed/NCBI
12	Mega JL, Simon T, Collet J-P, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, et al: Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: A meta-analysis. JAMA. 304:1821–1830. 2010.PubMed/NCBI View Article : Google Scholar
13	Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T and Wei W: Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis. 106:517–527. 2013.PubMed/NCBI View Article : Google Scholar
14	Chan NC, Eikelboom JW, Ginsberg JS, Lauw MN, Vanassche T, Weitz JI and Hirsh J: Role of phenotypic and genetic testing in managing clopidogrel therapy. Blood. 124:689–699. 2014.PubMed/NCBI View Article : Google Scholar
15	Hulot J-S, Collet J-P, Silvain J, Pena A, Bellemain-Appaix A, Barthélémy O, Cayla G, Beygui F and Montalescot G: Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: A systematic meta-analysis. J Am Coll Cardiol. 56:134–143. 2010.PubMed/NCBI View Article : Google Scholar
16	Frelinger AL III, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, et al: Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 61:872–879. 2013.PubMed/NCBI View Article : Google Scholar
17	Beitelshees AL, Voora D and Lewis JP: Personalized antiplatelet and anticoagulation therapy: Applications and significance of pharmacogenomics. Pharmgenomics Pers Med. 8:43–61. 2015.PubMed/NCBI View Article : Google Scholar